

**First Regular Session  
Seventy-second General Assembly  
STATE OF COLORADO**

**PREAMENDED**

*This Unofficial Version Includes Committee  
Amendments Not Yet Adopted on Second Reading*

LLS NO. 19-0082.02 Yelana Love x2295

**HOUSE BILL 19-1216**

---

**HOUSE SPONSORSHIP**

**Roberts, McCluskie**

**SENATE SPONSORSHIP**

**Donovan and Priola,**

---

**House Committees**

Health & Insurance  
Appropriations

**Senate Committees**

---

**A BILL FOR AN ACT**

101 **CONCERNING MEASURES TO REDUCE A PATIENT'S COSTS OF**  
102 **PRESCRIPTION INSULIN DRUGS.**

---

**Bill Summary**

*(Note: This summary applies to this bill as introduced and does not reflect any amendments that may be subsequently adopted. If this bill passes third reading in the house of introduction, a bill summary that applies to the reengrossed version of this bill will be available at <http://leg.colorado.gov>.)*

The bill requires a carrier to reduce the cost sharing a covered person is required to pay for prescription insulin drugs by an amount equal to the greater of 51% of the total rebates received by the carrier per prescription insulin drug including price protection rebates or an amount that ensures cost sharing will not exceed 125% of the carrier's cost for the prescription insulin drug, subject to a maximum out-of-pocket cost of

Shading denotes HOUSE amendment. Double underlining denotes SENATE amendment.  
Capital letters or bold & italic numbers indicate new material to be added to existing statute.  
Dashes through the words indicate deletions from existing statute.

\$100 per one-month supply of insulin.

The bill requires the department of law to investigate the pricing of prescription insulin drugs and submit a report of its findings to the governor, the commissioner of insurance, and the judiciary committees of the senate and house of representatives.

---

*Be it enacted by the General Assembly of the State of Colorado:*

**SECTION 1. Legislative declaration.** (1) The general assembly hereby finds and declares that:

(a) Almost twenty thousand Coloradans are diagnosed with diabetes each year. As of January 1, 2018, nearly three hundred thousand Colorado adults have been diagnosed with diabetes and another one hundred ten thousand are undiagnosed but living with the disease.

(b) Every Coloradan with type 1 diabetes and many with type 2 diabetes rely on daily doses of insulin to survive;

(c) The annual medical cost related to diabetes in Colorado is almost four billion dollars. Approximately eighteen percent of that amount, or seven hundred million dollars, is for prescription drugs to treat diabetes.

(d) Insulin prices rose by forty-five percent between 2014 and 2017, and over the last fourteen years, the price of insulin has risen by five hundred fifty-five percent, adjusted for inflation;

(e) One in four type 1 diabetics have reported insulin underuse due to the high cost of insulin; and

(f) Therefore, it is important to enact policies to reduce the costs for Coloradans with diabetes to obtain life-saving and life-sustaining insulin.

**SECTION 2.** In Colorado Revised Statutes, **add** 10-16-148 as follows:

1           **10-16-148. Cost sharing in prescription insulin drugs - limits**  
2           **- confidentiality of rebate information.** (1) AS USED IN THIS SECTION,  
3           UNLESS THE CONTEXT OTHERWISE REQUIRES:

4           (a) "COST SHARING" MEANS A **COPAYMENT** OR COINSURANCE  
5           AMOUNT IMPOSED ON A COVERED PERSON FOR A COVERED PRESCRIPTION  
6           DRUG IN ACCORDANCE WITH THE TERMS AND CONDITIONS OF THE  
7           COVERED PERSON'S HEALTH COVERAGE PLAN.

8           [REDACTED]  
9           (b) "PRESCRIPTION INSULIN DRUG" MEANS A PRESCRIPTION DRUG,  
10          AS DEFINED IN SECTION 12-42.5-102 (34), THAT CONTAINS INSULIN AND IS  
11          USED TO TREAT DIABETES.

12          [REDACTED]  
13          [REDACTED]  
14          (2) A CARRIER THAT PROVIDES COVERAGE AND, PURSUANT TO THE  
15          TERMS OF A HEALTH COVERAGE PLAN THE CARRIER OFFERS, IMPOSES A  
16          COST-SHARING AMOUNT FOR PRESCRIPTION INSULIN DRUGS SHALL CAP THE  
17          TOTAL AMOUNT OF COST SHARING THAT A COVERED PERSON IS REQUIRED  
18          TO PAY, INCLUDING [REDACTED] COST-SHARING AMOUNTS CHARGED ONCE A  
19          DEDUCTIBLE IS MET, AT AN AMOUNT NOT TO EXCEED **ONE HUNDRED**  
20          **DOLLARS PER THIRTY-DAY SUPPLY OF INSULIN, REGARDLESS OF THE**  
21          **AMOUNT OR TYPE OF INSULIN NEEDED TO FILL THE COVERED PERSON'S**  
22          **PRESCRIPTION.**

23          (3) NOTHING IN THIS SECTION PREVENTS A CARRIER FROM  
24          REDUCING A COVERED PERSON'S COST SHARING BY AN AMOUNT GREATER  
25          THAN THE AMOUNT SPECIFIED IN SUBSECTION (2) OF THIS SECTION.

26          [REDACTED] [REDACTED]  
27          (4) THE COMMISSIONER MAY USE ANY OF THE COMMISSIONER'S

1 ENFORCEMENT POWERS TO OBTAIN A CARRIER'S COMPLIANCE WITH THIS  
2 SECTION.

3 **SECTION 3.** In Colorado Revised Statutes, **add** 24-31-110 as  
4 follows:

5 **24-31-110. Department of law - investigate prescription insulin**  
6 **drug pricing - report - repeal.** (1) THE DEPARTMENT OF LAW SHALL  
7 INVESTIGATE PRICING OF PRESCRIPTION INSULIN DRUGS, AS DEFINED IN  
8 SECTION 10-16-148 (1)(b), MADE AVAILABLE TO COLORADO CONSUMERS  
9 TO ENSURE ADEQUATE CONSUMER PROTECTIONS IN PRICING OF  
10 PRESCRIPTION INSULIN DRUGS AND WHETHER ADDITIONAL CONSUMER  
11 PROTECTIONS ARE NEEDED.

12 (2) (a) AS PART OF THE INVESTIGATION BY THE DEPARTMENT OF  
13 LAW, THE DEPARTMENT OF LAW SHALL GATHER, COMPILE, AND ANALYZE  
14 INFORMATION CONCERNING THE ORGANIZATION, BUSINESS PRACTICES,  
15 PRICING INFORMATION, DATA, REPORTS, OR OTHER INFORMATION THAT  
16 THE DEPARTMENT OF LAW FINDS NECESSARY TO FULFILL THE  
17 REQUIREMENTS OF THIS SECTION FROM COMPANIES ENGAGED IN THE  
18 MANUFACTURE OR SALE OF PRESCRIPTION INSULIN DRUGS. THE  
19 DEPARTMENT OF LAW SHALL ALSO CONSIDER ANY PUBLICLY AVAILABLE  
20 INFORMATION RELATED TO DRUG PRICING.

21 (b) IF NECESSARY TO FULFILL THE REPORTING REQUIREMENTS OF  
22 THIS SECTION, THE ATTORNEY GENERAL MAY ISSUE A CIVIL INVESTIGATIVE  
23 DEMAND REQUIRING A STATE DEPARTMENT; CARRIER, AS DEFINED IN  
24 SECTION 10-16-102 (8); PHARMACY BENEFIT MANAGEMENT FIRM, AS  
25 DEFINED IN SECTION 10-16-102 (49); OR MANUFACTURER OF PRESCRIPTION  
26 INSULIN DRUGS THAT ARE MADE AVAILABLE IN COLORADO, TO FURNISH  
27 MATERIAL, ANSWERS, DATA, OR OTHER RELEVANT INFORMATION.

1 (3) A PERSON OR BUSINESS SHALL NOT BE COMPELLED TO PROVIDE  
2 TRADE SECRETS, AS DEFINED IN SECTION 7-74-102 (4).

3 (4) BY NOVEMBER 1, 2020, THE DEPARTMENT OF LAW SHALL ISSUE  
4 AND MAKE AVAILABLE TO THE PUBLIC A REPORT DETAILING ITS FINDINGS  
5 FROM THE INVESTIGATION CONDUCTED PURSUANT TO THIS SECTION. THE  
6 DEPARTMENT OF LAW SHALL PRESENT THE REPORT TO THE GOVERNOR, THE  
7 COMMISSIONER OF INSURANCE, AND THE JUDICIARY COMMITTEES OF THE  
8 SENATE AND HOUSE OF REPRESENTATIVES OR THEIR SUCCESSOR  
9 COMMITTEES. THE REPORT MUST INCLUDE:

10 (a) A SUMMARY OF INSULIN PRICING PRACTICES AND VARIABLES  
11 THAT CONTRIBUTE TO PRICING OF HEALTH COVERAGE PLANS, AS DEFINED  
12 IN SECTION 10-16-102 (34);

13 (b) PUBLIC POLICY RECOMMENDATIONS TO CONTROL AND PREVENT  
14 OVERPRICING OF PRESCRIPTION INSULIN DRUGS MADE AVAILABLE TO  
15 COLORADO CONSUMERS;

16 (c) ANY RECOMMENDATIONS FOR IMPROVEMENTS TO THE  
17 "COLORADO CONSUMER PROTECTION ACT", ARTICLE 1 OF TITLE 6, TO  
18 PREVENT DECEPTIVE SALES PRACTICES RELATED TO THE SALE OF  
19 PRESCRIPTION INSULIN DRUGS, INCLUDING THE PRICING OF THOSE DRUGS;  
20 AND

21 (d) ANY OTHER INFORMATION THE DEPARTMENT OF LAW FINDS  
22 NECESSARY.

23 (5) THIS SECTION IS REPEALED, EFFECTIVE DECEMBER 1, 2020.

24 **SECTION 4. Act subject to petition - effective date -**  
25 **applicability.** (1) This act takes effect at 12:01 a.m. on the day following  
26 the expiration of the ninety-day period after final adjournment of the  
27 general assembly (August 2, 2019, if adjournment sine die is on May 3,

1 2019); except that, if a referendum petition is filed pursuant to section 1  
2 (3) of article V of the state constitution against this act or an item, section,  
3 or part of this act within such period, then the act, item, section, or part  
4 will not take effect unless approved by the people at the general election  
5 to be held in November 2020 and, in such case, will take effect on the  
6 date of the official declaration of the vote thereon by the governor.

7 (2) This act applies to health coverage plans issued or renewed on  
8 or after January 1, 2020, or the date of the official declaration of the vote  
9 by the governor, whichever is later.